A Study of JNJ-75276617 in Combination With Acute Myeloid Leukemia (AML) Directed Therapies
Status:
Not yet recruiting
Trial end date:
2024-12-26
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the recommended Phase 2 dose (RP2D) candidate(s) of
JNJ-75276617 in combination with AML directed therapies (dose selection) and further to
evaluate safety and tolerability of JNJ-75276617 in combination with AML directed therapies
at the RP2D(s) (dose expansion).